Get started
Author

Laura Deiana

Observed names: L. Deiana, Laura DEIANA
ORCID: 0000-0003-3252-9921
Observed ORCID: 0000-0003-3252-9921
OpenAlex ID: A5103194194
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
2022 · François-Clément Bidard, Anne-Claire Hardy-Bessard, et al. · The Lancet Oncology · 404
PDF
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
2026 · Nicoletta Colombo, Emese Zsiros, et al. · The Lancet · 75
Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial
2025 · Hervé Bonnefoi, Florence Lerebours, et al. · The Lancet Oncology · 29
213MO Primary endpoint analysis of a randomized phase II of darolutamide or capecitabine in patients with triple-negative androgen receptor-positive advanced breast cancer (UCBG3-06 START trial)
2022 · M. Arnedos, A. Goncalves, et al. · Annals of Oncology · 8
167MO Association between ER, PR and HER2 levels and outcome under palbociclib (Pal) + aromatase inhibitors (AIs) as first-line therapy for ER+ HER2- metastatic breast cancer (MBC): An exploratory analysis of the PADA-1 trial
2022 · T. De La Motte Rouge, J-S. Frenel, et al. · Annals of Oncology · 8
PDF
23 An attempt to correlate ‘comprehensive geriatric assessment’ (CGA), treatment assignment and clinical outcome in elderly cancer patients: preliminary results of a phase II open study
2006 · E. Massa, G. Astara, et al. · Critical Reviews in Oncology/Hematology · 8
Aspergillosis Superinfection as a Cause of Death of Crizotinib-Induced Interstitial Lung Disease Successfully Treated with High-Dose Corticosteroid Therapy
2015 · Laura Deiana, Salvatore Grisanti, et al. · Case Reports in Oncology · 5
Breast cancer tumor heterogeneity has only little impact on the estimation of the Oncotype DX® recurrence score using Magee Equations and Magee Decision Algorithm™
2020 · Annabelle Remoué, Virginie Conan-Charlet, et al. · Human Pathology · 3
PDF
Patient-reported outcomes from ENGOT-ov65/KEYNOTE-B96: a phase 3, randomized, double-blind study of pembrolizumab vs placebo plus paclitaxel with or without bevacizumab for platinum-resistant recurrent ovarian cancer
2026 · Emese Zsiros, Rutie Yin, et al. · International Journal of Gynecological Cancer · 1
Clinical outcome of advanced or recurrent endometrial carcinoma treated with chemotherapy: a French observational retrospective cohort: the ENDOVIE study
2025 · Jerome Alexandre, Philippe Boudier, et al. · BMJ Open · 1
Stereotactic body radiotherapy for oligometastatic ovarian cancer: Current evidence, patient selection, and future directions
2026 · François Lucia, Laura Deiana, et al. · Cancer/Radiothérapie
PDF
427P Effectiveness and safety of talazoparib in patients with HER2-negative metastatic breast cancer harboring a BRCA1/2 mutation: Final analysis from the phase IV ViTAL study
2026 · D. Loirat, W. Jacot, et al. · ESMO Open
Patient-reported outcomes from the phase 3 ENGOT-ov65/KEYNOTE-B96 trial of pembrolizumab versus placebo plus paclitaxel, with or without bevacizumab, in platinum-resistant recurrent ovarian cancer
2026 · Emese Zsiros, Rutie Yin, et al. · Gynecologic Oncology
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2024–2025 : prise en charge du cancer du col de l’utérus avancé
2026 · Renaud Sabatier, Christophe Hennequin, et al. · Bulletin du Cancer
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2024–2025 : prise en charge cardio-oncologique des principaux schémas thérapeutiques en onco-gynécologie
2026 · Olivia Le Saux, Elvire Mervoyer, et al. · Bulletin du Cancer
1133P GREAT: Clinical outcomes from a prospective study of 1,456 patients (pts) with advanced ovarian cancer (AOC), including theranostic biomarker analysis (BRCA and genomic instability score) and paired tumor/DNA collection in the PARP inhibitor era
2025 · T. De La Motte Rouge, L. Deiana, et al. · Annals of Oncology
Outcome and follow-up of glioblastoma patients treated with bevacizumab based therapy in 2nd lign treatment.
2016 · Benjamin Auberger, Marie Robert, et al. · Journal of Clinical Oncology
Association of decrease of left ventricular ejection fraction with overall survival benefit in trastuzumab treated metastatic esogastric cancer patients.
2016 · Jerome Martin-Babau, Yves Eusen, et al. · Journal of Clinical Oncology
Works count: 18
Citation count: 542
H-index: 6
I10-index: 3
Year
Topic
Type